MapLight Therapeutics (MPLT) Non Operating Income (2024 - 2025)
MapLight Therapeutics (MPLT) reported Non Operating Income of $3.8 million for Q4 2025, up 147.35% on a YoY basis from $1.5 million in Q4 2024, and up 84.09% sequentially from $2.1 million in Q3 2025.
MapLight Therapeutics (MPLT) Non Operating Income (2024 - 2025) Analysis & Trends
MapLight Therapeutics (MPLT) has 2 years of Non Operating Income data on file, last reported at $3.8 million in Q4 2025.
- For the quarter ending Q4 2025, Non Operating Income rose 147.35% year-over-year to $3.8 million; the trailing twelve-month figure through Dec 2025 stood at $9.3 million (changed N/A YoY), and the FY2025 full-year result was $7.9 million, up 47.8% from the prior year.
- Non Operating Income grew to $3.8 million in Q4 2025, from $2.1 million in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $3.8 million in Q4 2025 to a low of $1.5 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -9.22 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 444,000.00 |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 188.30 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | 5.75 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -8.59 Mn |
| 10 | MapLight Therapeutics | 314.07 Mn | 314.07 Mn | - | 3.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.83 Mn |
| Sep 30, 2025 | 2.08 Mn |
| Dec 31, 2024 | 1.55 Mn |
| Sep 30, 2024 | 1.88 Mn |